Publicacións en colaboración con investigadores/as de Universitat Autònoma de Barcelona (20)

2025

  1. Copper(II) Cyclopeptides with High ROS-Mediated Cytotoxicity

    Bioconjugate Chemistry, Vol. 36, Núm. 3, pp. 500-509

2024

  1. Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients

    Journal of Infection

  2. Stepwise Structural Simplification of the Dihydroxyanthraquinone Moiety of a Multitarget Rhein-Based Anti-Alzheimer Lead to Improve Drug Metabolism and Pharmacokinetic Properties

    Pharmaceutics, Vol. 16, Núm. 8

2022

  1. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 236

  2. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4909-4925

  3. Insights into the Pharmacokinetics and In Vitro Cell‐Based Studies of the Imidazoline I2 Receptor Ligand B06

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

2021

  1. Benzofuranyl-2-imidazoles as imidazoline I2 receptor ligands for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 222

  2. From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects

    European Journal of Medicinal Chemistry, Vol. 225

  3. Modeling ANXA2-overexpressing circulating tumor cells homing and high throughput screening for metastasis impairment in endometrial carcinomas

    Biomedicine and Pharmacotherapy, Vol. 140

2020

  1. Bicyclic α-Iminophosphonates as High Affinity Imidazoline I2 Receptor Ligands for Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 63, Núm. 7, pp. 3610-3633

  2. Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6

    Journal of Medicinal Chemistry, Vol. 63, Núm. 17, pp. 9360-9390

  3. Pharmacological Inhibition of Soluble Epoxide Hydrolase as a New Therapy for Alzheimer’s Disease

    Neurotherapeutics, Vol. 17, Núm. 4, pp. 1825-1835

  4. Pharmacology and preclinical validation of a novel anticancer compound targeting PEPCK-M

    Biomedicine and Pharmacotherapy, Vol. 121

2010

  1. Phe369(7.38) at human 5-HT 7 receptors confers interspecies selectivity to antagonists and partial agonists

    British Journal of Pharmacology, Vol. 159, Núm. 5, pp. 1069-1081

2008

  1. Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2′-furyl)-1,2,4-triazolo[1,5-a]quinoxalines

    Bioorganic and Medicinal Chemistry, Vol. 16, Núm. 4, pp. 2103-2113

1998

  1. Comparison of electrostatic similarity approaches applied to a series of ketanserin analogues with 5-HT(2A) antagonistic activity

    Quantitative Structure-Activity Relationships, Vol. 17, Núm. 3, pp. 199-204

1997

  1. Synthesis, affinity at 5-HT(2A), 5-HT(2B) and 5-HT(2C) serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues

    Chemical and Pharmaceutical Bulletin, Vol. 45, Núm. 5, pp. 842-848

1993

  1. Antiserotoninergic activity of 2‐aminoethylbenzocyclanones in rat aorta: Structure‐activity relationships

    Journal of Pharmaceutical Sciences, Vol. 82, Núm. 5, pp. 513-517

  2. Cyproheptadine analogues: Synthesis, antiserotoninergic activity, and structure‐activity relationships

    Journal of Pharmaceutical Sciences, Vol. 82, Núm. 11, pp. 1090-1093

  3. Study of the mechanism of the relaxant action of (+)‐glaucine in rat vas deferens

    British Journal of Pharmacology, Vol. 110, Núm. 3, pp. 943-948